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nationally agreed upon. This case
illustrates another potential pitfall in
melioidosis serodiagnosis. Most iso-
lates express a conserved LPS antigen,
which allows use of a single reference
strain for determination of anti-LPS
antibodies (8). However, because
some strains express different LPS
antigens, serologic tests must be per-
formed with the patient’s own strain.
This case illustrates potential pit-
falls in diagnosing melioidosis, which
requires clinical and laboratory aware-
ness and knowledge of its geographic
distribution. LPS-based serologic
assays should use a range of isolates
representative of known LPS types.
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Subclinical
Plasmodium 
falciparum
Infection and HIV-1
Viral Load 
To the Editor: Studies indicate
that Plasmodium falciparum infection
increases HIV replication in adults
(1,2). Although malaria-related illness
and death are more common in chil-
dren, and HIV-1 generally progresses
faster in children than in adults (3,4),
to our knowledge the effect of inter-
mittent malaria on HIV-1 viral load
has not been directly explored in chil-
dren. To investigate this issue, we
monitored HIV-positive infants from
a 1996–2001 birth cohort study in
Kisumu, Kenya, a P. falciparum–
holoendemic area.
Study design and methods have
been described elsewhere (5,6).
Twenty-four children that were peri-
natally infected with HIV were
included in this substudy. During
monthly visits during the child’s first
2 years of life, malaria and HIV inci-
dence were recorded (5,6). Both chil-
dren with malaria-positive blood
smears and those with fever but no
smear result available were treated
with sulfadoxine-pyrimethamine
according to national guidelines. At
the time of this substudy, none of the
study participants were taking anti-
retroviral drugs.
HIV and malaria diagnoses were
determined by using standard meth-
ods (5–7). To reduce the chance of
including infants infected through
breast-feeding, perinatal infection was
defined as >2 consecutive HIV-posi-
tive tests, with the first positive PCR
result by 4 months of age (7). The so-
called baseline viral load was the pre-
malaria value measured 1 month
before the first observation in the
analysis. To be included in the analy-
sis, follow-up visits had to have data
available on the current and previous
months’ viral load and malaria status
and occur at roughly monthly inter-
vals at >4 months of age.
Malaria parasites were found at 53
of 146 visits in the month before viral
load measurement, although at 89%
of visits in which children were
malaria-positive, the children’s sam-
ples had <1,000 parasites/µL, and in
only 13% of visits in which children
had parasitemia did they also have
fever (8). Median number of observa-
tions per child was 7 (range 2–18). No
significant demographic or clinical
differences were found between HIV-
positive children in this substudy and
those enrolled in the full cohort (data
not shown).
Clinical and demographic vari-
ables were evaluated in univariate
repeated measures analysis to deter-
mine associations with log-trans-
formed HIV-1 viral load. Age andLETTERS
baseline viral load were strong predic-
tors of current load (Table). Although
not statistically significant, clearing
the previous month’s malaria infec-
tion was associated with a drop in
viral load (Table, p = 0.09). It was not
possible to distinguish between the
effects of treatment versus malaria
clearance because 87% of malaria
infections were treated with anti-
malarial drugs. However, viral load
increased in those incorrectly treated
for malaria presumptively (Table).
After adjusting for age and base-
line viral load, we assessed log10 HIV
viral load in relation to malaria clear-
ance, persistence, absence, or new
infection using a repeated measures
model with autoregressive covariance
structure. No differences were statisti-
cally significant, although clearing an
infection versus no malaria had a 0.22
log viral load decrease (Table, p =
0.10). When 15 malaria episodes with
malaria-free visits 1 month before and
after the episode were compared,
mean difference (signed-rank test) in
viral load “before” and “after” malar-
ia was not significant.
Our findings suggest that low-den-
sity malaria infection may not dramat-
ically affect plasma HIV-1 levels in
infants. This finding is similar to
results of studies of perinatally HIV-
infected children in which, although
viral loads were unavailable, number
of malaria episodes did not signifi-
cantly affect development of AIDS-
related symptoms (9,10). While clini-
cal malaria leads to at least short-term
HIV viral load increases in adults
(1,2), the effect of subclinical malaria
is unclear, and even less is known
about coinfection in children.
Children usually have higher baseline
viral loads than adults; thus, the rela-
tive effect of malaria on viral load
may not be as great. To reduce the
impact of passively transferred mater-
nal antibodies, analyses were done on
visits after the child was 4 months old.
However, lack of fully acquired anti-
malarial immunity may have led to
different HIV/malaria interactions
than seen in adults.
Viral load increased in infants that
were incorrectly treated presumptive-
ly (due to fever) for malaria (Table).
Most of these children were found to
have other infections. Fever in malar-
ia-endemic areas is often assumed to
be malaria-related, but delay in treat-
ment of nonmalarial infections may
be harmful in HIV-infected children
Our assessment was limited in size
and duration. Furthermore, in attempt-
ing to provide optimal patient care
through conducting monthly surveil-
lance and encouraging mothers to
bring children in during febrile
episodes, ability to assess the effect of
high-density malaria was diminished
because parasitemia levels never
reached clinically significant levels.
Finally, because malaria was diag-
nosed by microscopy, rather than
PCR, some subclinical malaria infec-
tions may have been misclassified as
malaria-negative.
Although we found no evidence of
an association between subclinical,
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low-density malaria and infant HIV-1
viral load, the consequences of high-
density or clinical malaria need to be
explored. If clinical malaria in infants
increases HIV-1 viral load as it does
in adults (1,2), our study underscores
dual benefits of malaria treatment in
the context of HIV: 1) keeping malar-
ia in check, and 2) preventing an
increase in HIV viral load. Ethical
issues prevent prospective studies to
assess the impact of coinfection early
in life, but alternatives include using
animal models or stored specimens.
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African Tickbite
Fever in Travelers,
Swaziland 
To the Editor: African tickbite
fever (ATBF), which is caused by
Rickettsia africae, is well documented
in travelers to southern Africa (1–3)
and transmitted by ungulate ticks of
the genus Amblyomma. Positive sero-
logic results were reported in 9% of
patients (1) and 11% of travelers (4)
from southern Africa. We report an
outbreak of ATBF with an attack rate
of 100% among 12 Dutch travelers to
Swaziland.
The 12 travelers (9 male and 3
female) visited Mkhaya Game
Reserve in Swaziland in May 2003 for
several days. Upon retuning to the
Netherlands, they consulted our clinic
for assessment for fever, malaise, and
skin eruptions. Epidemiologic and
clinical data were obtained after the
patients provided informed consent.
All symptomatic patients were treated
before serum samples were collected. 
Acute-phase and convalescence-
phase serum samples were obtained
from 8 patients at 3 and 9 weeks,
respectively, after symptoms were
reported. Only convalescent-phase
serum samples were obtained from
the other 4 patients. Serologic assays
were conducted for screening and
confirmation in Rotterdam, the
Netherlands (Department of Virology,
Erasmus University Hospital) and
Marseille, France (Unité des
Rickettsies, Faculté de Médecine,
Université de la Mediterranée),
respectively. 
In Rotterdam, immunofluores-
cence assays for immunoglobulin G
(IgG) and IgM against R. conorii, R.
typhi, and R. rickettsii were per-
formed with multiwell slides on
which antigens were fixed (Panbio
Inc., Columbia, MD, USA). Serum
samples with fluorescent rickettsiae
at dilutions >1:32 were considered
positive.
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